Evidation is expanding its decade-long collaboration with Sanofi to build upon their joint real-world data initiatives. This new phase will focus on the co-development of unique datasets to develop and validate new measures of health and wellness. Evidation's collaboration with Sanofi has delivered results to date, with over 20 studies conducted across 10 therapeutic areas, including diabetes and Type 2 Inflammation, more than 500,000 patients reached, and four studies published.

This continued collaboration will further the work Evidation and Sanofi have pioneered to translate person-generated health data into quantified clinical and economic outcomes, a key priority for both companies. Sanofi and Evidation announced a prior expansion of their work together in 2017, in addition to Sanofi's investment in Evidation in the same year.